 |
|
15th
World Congress Clinical Nutrition
19th
– 22nd September 2010 El Sokhna Resort - Egypt
|
 |
|
|
| |
 |
Copyright © 2010.
WCCN2010.COM
All rights reserved |
|
 |
 |
How Coenzyme Q10 and N-3 PUFA affect
cardiovascular health
D Pella , J Fedacko, R Rybar, V
Vargova, D Trejbal
3rd Internal Clinic, Faculty of
Medicine PJ Safarik University Louis
Pasteur Hospital, Kosice, Slovakia
|
Objective
Coenzyme Q10 ( CoQ10, ubiquinone,
ubidekarenone ) is a substance which
may improve endothelial dysfunction
( key risk factor for several
cardiovascular diseases ) having
antioxidant, antiinflammatory,
vasodilatory and antiproliferative
effects. Growing evidence has
suggested an important role of
omega-3 polyunsaturated fatty acids
( n-3 PUFA ) in reducing risk of
cardiovascular disease in the
general population and patients with
preexisting heart disease. To date,
beneficial cardioprotective effects
of n-3 PUFA are attributed to their
antiarrhythmic, lipid lowering,
antithrombotic and anti-inflammatory
properties. In addition, these acids
favourably influence individual
components of the metabolic
syndrome, with the exception of
glucose homeostasis.
Methods
We searched Medline database (
1980-2007 ) for epidemiological,
experimental and clinical studies
dealing with cardioprotective
effects of CoQ10 and/or n-3 PUFA.
Articles were screened for their
relevance to this specific topic and
included were only selected studies
published in peer-reviewed journals.
Design and the most important
clinical results and conclusions
from the relevant clinical studies
with n-3 PUFA and CoQ10 were
reviewed.
Results
Ubiquinone is very important
substance in myocardial energetic
metabolism and stability of cells
membrane as well, when deficient,
myocytes should be prone to damage
in the form of myopathy or myositis,
or even rhabdomyolysis. Several
clinical studies have shown
beneficial effects of CoQ10
supplementation in patients with
statin-associated myopathy or left
ventricular diastolic dysfunction.
Moreover, blood pressure lowering
and positive effects in patients
with heart failure have been
documented.
Omega-3 fatty acids, derived
especially from fish and certain
green plants, are useful in large
doses for lowering serum
triglyceride levels ( especially for
combined treatment with statins in
patients with mixed dyslipidaemia
due to their complementary effects
on atherogenic blood lipids ), but
the primary benefits are likely to
arise from smaller, nutritional
intakes of eicosapentaenoic acid and
docosahexaenoic acid. They have also
been shown to have a direct effect
on myocardial contractility, blood
pressure, platelet function,
coagulation factors, cell-mediated
immunity and markers of
inflammation. Several long-term
epidemiologic and randomized
clinical studies have found an
inverse association between
increased n-3 fatty acids
consumption and risk of coronary
heart disease or stroke. Moreover,
increased consumption of omega-3
fatty acids is valuable in
preventing sudden cardiac death.
Last, but not least, recent studies
showed that a high ratio of
omega-6/omega-3 fatty acids is
detrimental and may lead to the
development of chronic diseases
including coronary heart disease.
Conclusions
Several breakthrough clinical
studies have changed the perceptions
of omega3 and CoQ10 as being rather
dietary supplements to becoming
currently established medicaments.
Finally, pleiotropic effects of
statins, CoQ10, and n-3 PUFA are
complementary or additive, but
apparently beneficial for the
patients. However, despite these
positive findings there is still a
need to further investigation of the
clinical effectiveness of omega3
and/or CoQ10 ( and/or statins ) in
forthcoming double-blind randomized
clinical studies
|
|
| |
|
 |
|
:: :: :: :: |
|
